A potassium channel, the M-channel, as a therapeutic target

Current Opinion in Investigational Drugs

Volumn 6, Issue 7, 2005, Pages 704-711

  Surti, Toral S ^a   Jan, Lily Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticonvulsant; Benign familial neonatal convulsions; Epilepsy; KCNQ; Linopirdine; Potassium channel; Retigabine

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; ACRYLAMIDE DERIVATIVE; ANTICONVULSIVE AGENT; BENZAMIDE DERIVATIVE; FLUPIRTINE; LINOPIRDINE; N [1 (3 MORPHOLIN 4 YLPHENYL)ETHYL] 3 PHENYLACRYLAMIDE; N [1 (4 CYCLOPROPYLMETHYL 3,4 DIHYDRO 2H BENZO[1,4]OXAZIN 6 YL)ETHYL] 3 (2 FLUORO PHENYL)ACRYLAMIDE; N [1 (4 FLUORO 3 MORPHOLIN 4 YLPHENYL)ETHYL] 3 (4 FLUOROPHENYL)ACRYLAMIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNQ1; POTASSIUM ION; RETIGABINE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ALZHEIMER DISEASE; AMNESIA; ANXIETY; BIPOLAR DISORDER; BRAIN NERVE CELL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; DEMENTIA; DEVELOPMENTAL COORDINATION DISORDER; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MIGRAINE; MUSCLE WEAKNESS; NERVE EXCITABILITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; REVIEW; SEIZURE; SOMNOLENCE; SPEECH DISORDER; STROKE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VERTIGO;

ANIMALS; CARBAMATES; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS; HUMANS; INDOLES; MOLECULAR STRUCTURE; PHENYLENEDIAMINES; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRIDINES;

EID: 21344462822     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. + current in a vertebrate neurone. Nature (1980) 283(5748):673-676.
2. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D: KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science (1998) 282(5395):1890-1893.
3. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinfein OK: A potassium channel mutation in neonatal human epilepsy. Science (1998) 279(5349):403-406.
4. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, McHarg MIL et al: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet (1998) 18(1):25-29.
5. Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, Leppert M: A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet (1998) 18(1):53-55.
6. Brown BS, Yu SP: Modulation and genetic identification of the M channel. Prog Biophys Mol Biol (2000) 73(2-4):135-166.
7. Marrion NV: Control of M-current. Annu Rev Physiol (1997) 59:483-504.
8. Jentsch TJ: Neuronal KCNQ potassium channels: Physiology and role in disease. Nat Rev Neurosci (2000) 1(1):21-30.
9. Yang WP, Levesque PC, Little WA, Conder ML, Ramakrishnan P, Neubauer MG, Blanar MA: Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J Biol Chem (1998) 273(31):19419-19423.
10. Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, Busch AE, Steinmeyer K: Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J Biol Chem (2000) 275(29):22395-22400.
11. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ: KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Blol Chem (2000) 275(31):24089-24095.
12. + channel subunit, Erg1 and KCNQ2/3, contribute to the M-like current in a mammalian neuronal cell. J Neurosci (1999) 19(18):7742-7756.
13. Selyanko AA, Delmas P, Hadley JK, Tatulian L, Wood IC, Mistry M, London B, Brown DA: Dominant-negative subunits reveal potassium channel families that contribute to M-like potassium currents. J Neurosci (2002) 22(5): RC212.
14. Robbins J: KCNO potassium channels: Physiology, pathophysiology, and pharmacology. Pharmacol Ther (2001) 90(1):1-19.
15. + channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA (2000) 97(8):4333-4338.
16. Cooper EC, Harrington E, Jan YN, Jan LY: M channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J Neurosci (2001) 21(24):9529-9540.
17. Cooper EC, Aldape KD, Abosch A, Barbaro NM, Berger MIS, Peacock WS, Jan YN, Jan LY: Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. Proc Natl Acad Sci USA (2000) 97(9):4914-4919.
18. Yus-Najera E, Munoz A, Salvador N, Jensen BS, Rasmussen HB, Defelipe J, Villarroel A: Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience (2003) 120(2):353-364.
19. + channel. J Neurosci (2004) 24(5):1236-1244.
20. + channels and the molecular pathogenesis of epilepsy: Implication for therapy. Trends Neurosci (2000) 23(9):393-398.
21. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ et al: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet (1996) 12(1):17-23.
22. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, Cournel P, Petit C, Schwartz K, Guicheney P: A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet (1997) 15(2):186-189.
23. Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, EI-Amraoui A, Marlin S, Petit C, Jentsch TJ: KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell (1999) 96(3):437-446.
24. Dedek K, Fusco L, Teloy N, Steinlein OK: Neonatal convulsions and epileptic encephalopathy in an Italian family with a missense mutation in the fifth transmembrane region of KCNQ2. Epilepsy Res (2003) 54(1):21-27.
25. + channels causes epilepsy. Nature (1998) 396(6712):687-690.
26. + channel. Proc Natl Acad Sci USA (2001) 98(21):12272-12277.
27. Castaldo P, del Giudice EM, Coppola G, Pascotto A, Annunziato L, Taglialatela M: Benign familial neonatal convulsions caused by altered gating of KCNQ2/KCNQ3 potassium channels. J Neurosci (2002) 22(2):RC199.
28. Watanabe H, Nagata E, Kosakai A, Nakamura M, Yokoyama M, Tanaka K, Sasai H: Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J Neurochem (2000) 75(1):28-33.
29. Yang Y, Beyer BJ, Otto JF, O'Brien TP, Letts VA, White HIS, Frankel WN: Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. Hum Mol Genet (2003) 12(9):975-984.
30. Peters HC, Hu H, Pongs O, Storm JF, Isbrandt D: Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci (2005) 8(1):51-60.
31. Yonekawa WD, Kapetanovic IM, Kupterberg HJ: The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro. Epilepsy Res (1995) 20(2):137-150.
32. Dailey JW, Cheong JH, Ko KH, Adams-Curtis LE, Jobe PC: Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: Prediction of clinical response. Neurosci Lett (1995) 195(2):77-80.
33. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Loscher W, Honack D, White HS, Wolf HH: D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res (1996) 23(3):211-223.
34. Tober C, Rostock A, Rundfeldt C, Bartsch R: D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol (11996) 303(3):163-169.
35. + channels in neuronal cells. Eur J Pharmacol (1997) 336(2-3):243-249.
36. + channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res (1999) 35(2):99-107.
37. Rundfeldt C, Netzer R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett (2000) 282(1-2):73-76.
38. Tatulian L, Delmas P, Abogadie FC, Brown DA: Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci (2001) 21(15):5535-5545.
39. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK: Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/03 potassium channels. Mol Pharmacol (2000) 58(3):591-600.
40. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol (2000) 58(2):253-262.
41. Wickenden AD, Zou A, Wagoner PK, Jegla T: Characterization of KCNQ5/03 potassium channels expressed in mammalian cells. Br J Pharmacol (2001) 132(2):381-384.
42. Schroder RL, Jespersen T, Christophersen P, Strobaek D, Jensen BS, Olesen SP: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40(7):888-898.
43. Dupuis DS, Schroder RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, Olesen SP: Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J Pharmacol (2002) 437(3):129-137.
44. Wuttke TV, Seebohm G, Bail S, Maijevic S, Lerche H: The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol (2005) 67(4):1009-1017.
45. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E: Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res (2002) 51(1-2):31-71.
46. Rogawski MA, Loscher W: The neurobiology of antiepileptic drugs. Nat Rev Neurosci (2004) 5(7):553-564.
47. Kwan P, Brodie MJ: Early identification of refractory epilepsy. N Engl J Med (2000) 342(5):314-319.
48. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E: Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res (2001) 43(1):11-58.
49. Wu YJ, Sun LQ, He H, Chen J, Starrett JE Jr, Dextraze P, Daris JP, Boissard CG, Pieschl RL, Gribkoff VK, Natale J et al: Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yi)-ethyl, and N-[1-(2,3-dihydro-1 H-indol-5-yl)-ethyl acrylamides. Bioorg Med Chem Lett (2004) 14(17):4533-4537.
50. Wu YJ, He H, Sun LQ, L'Heureux A, Chen J, Dextraze P, Starrett JE Jr, Boissard CG, Gribkoff VK, Natale J, Dworetzky SI: Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers. J Med Chem (2004) 47(11):2887-2896.
51. Wu YJ, Boissard CG, Chen J, Fitzpatrick W, Gao Q, Gribkoff VK, Harden DG, He H, Knox RJ, Natale J, Pieschl RL et al: (S)-N-[l-(4-cyclopropylmethyl-3, 4-dihydro-2H-benzo[1,4]oxazin-6-yl) -ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons. Bioorg Med Chem Lett (2004) 14(8):1991-1995.
52. Wu YJ, Boissard CG, Greco C, Gribkoff VK, Harden DG, He H, L'Heureux A, Kang SH, Kinney GG, Knox RJ, Natale J et al: (S)- N[1-(3-morphoIin-4-ylphenyl)ethyl]- 3-phenylacrylamide: An orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J Med Chem (2003) 46(15):3197-3200.
53. Wu YJ, Davis CD, Dworetzky S, Fitzpatrick WC, Harden D, He H. Knox RJ, Newton AE, Philip T, Polson C, Sivarao DV et al: Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: Identification of (S)-AP[1-(4-fIuoro-3- morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J Med Chem (2003) 46(18):3778-3781.
54. Rogawski MA, Loscher W: The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med (2004) 10(7):685-692.
55. Rasband MN, Park EW, Vanderah TW, Lai J. Porreca F, Trimmer JS: Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci USA (2001) 98(23):13373-13378.
56. Ishikawa K, Tanaka M, Black JA, Waxman SG: Changes in expression of voltage-gated potassium channels in dorsal root ganglion neurons following axotomy. Muscle Nerve (1999) 22(4):502-507.
57. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, Dickenson AH, Brown TA, Burbidge SA, Main M, Brown DA: KCNQ/M currents in sensory neurons: Significance for pain therapy. J Neurosci (2003) 23(18):7227-7236.
58. Blackburn-Munro G, Jensen BS: The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol (2003) 460(2-3):109-116.
59. Ilyin VI, Carlin KP, Hodges DD, Robledo S, Woodward RM: Flupirtine - a positive modulator of heteromeric KCNQ2/Q3 channels. Abs Soc Neuroscience (2002) 32:Abs 758.1.
60. Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, Johnson G et al: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med (2001) 7(4):471-477.
61. Hewawasam P, Chen N, Ding M, Natale JT, Boissard CG, Yeola S, Gribkotf VK, Starrett J, Dworetzky SI: The synthesis and structure-activity relationships of 3-amino-4-benzylquinolin-2-ones; discovery of novel KCNQ2 channel openers. Bioorg Med Chem Lett (2004) 14(7):1615-1618.
62. Nickolson VJ, Tam WS, Myers MJ, Cook L: DuP 996 (3,3-bis(4-pyrindinylmethyl)-l-phenylindolin-2-one) enhances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Dev Res (1990) 19(3):285-300.
63. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, Rominger DH, Earl RA: Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: Comparison to linopirdine. J Pharmacol Exp Ther (1998) 285(2):724-730.
64. Cook L, Nickolson VJ, Steinfels GF, Rohrbach KW, DeNoble VJ: Cognition enhancement by the acetylcholine releaser DuP 996. Drug Dev Res (1990) 19(3):301-314.
65. Rockwood K, Beattie BL, Eastwood MR, Feldman H, Mohr E, Pryse-Phillips W, Gauthier S: A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Can J Neurol Sci (1997) 24(2):140-145.
66. M) and some other voltage- and ligand-gated membrane currents in rat sympathetic neurons. Eur J Neurosci (1997) 9(3):605-616.
67. + channel assembly. EMBO Rep (2003) 4(l):76-81.
68. Hadley JK, Passmore GM, Tatulian L, Al-Qatari M, Ye F, Wickenclen AD, Brown DA: Stoichiometry of expressed KCNQ2/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. J Neurosci (2003) 23(12):5012-5019.